Gerald Staedtler Selected Research

Therapeutics

2/2021

Dual Vasopressin Receptor Antagonism to Improve Congestion in Patients With Acute Heart Failure: Design of the AVANTI Trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gerald Staedtler Research Topics

Disease

6	Rosacea (Acne Rosacea) 01/2017 - 06/2010
1	Body Weight (Weight, Body) 02/2021
1	Heart Failure 02/2021
1	Anemia 01/2019
1	Hypoxia (Hypoxemia) 01/2019
1	Chronic Renal Insufficiency 01/2019
1	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2017
1	Erythema 09/2016

Drug/Important Bio-Agent (IBA)

5	azelaic acid (Azelex)FDA Link 10/2016 - 06/2010
2	Immunoglobulin A (IgA)IBA 01/2017 - 09/2016
1	Antidiuretic Hormone Receptor AntagonistsIBA 02/2021
1	Urea (Carbamide)FDA LinkGeneric 02/2021
1	Sodium Potassium Chloride Symporter Inhibitors (Loop Diuretics)IBA 02/2021
1	Vasopressin Receptors (Arginine Vasopressin Receptor)IBA 02/2021
1	CreatinineIBA 02/2021
1	NitrogenIBA 02/2021
1	molidustatIBA 01/2019
1	HematinicsIBA 01/2019
1	Prolyl-Hydroxylase InhibitorsIBA 01/2019
1	R- 1,1,1- trifluoro- 4- (5- fluoro- 2,3- dihydrobenzofuran- 7- yl)- 4- methyl- 2- (((2- methyl- 5- quinolyl)amino)methyl)pentan- 2- olIBA 01/2017
1	Ointments (Pastes)IBA 01/2017
1	Metronidazole (Metric)FDA LinkGeneric 06/2010
1	Doxycycline (Periostat)FDA LinkGeneric 06/2010

Therapy/Procedure

1	Therapeutics 02/2021